“The diagnosis of NASH can be difficult, as most patients in early stages of the disease have no symptoms. The identification of patients is currently not possible by a typical physical examination.”
The Wall Street Journal – A Big, Fatty Opportunity for Big Pharma.
“Signs of the disease are asymptomatic, so a person often is not diagnosed with NASH until it advances to a late stage, when cirrhosis begins to ravage the body”.
CNBC – The $35 billion race to cure a silent killer that affects 30 million Americans.
Liver Disease Prevalence
Fatty liver disease has reached epidemic proportions worldwide, affecting over 20% of the population and increasing at a remarkable pace.
Nonalcoholic steatohepatitis (NASH), the progressive form of Non-alcoholic fatty liver disease (NAFLD), can lead to cirrhosis, cardiovascular problems, hepatocellular carcinoma, and even death.
Liver disease is reversible if detected early on. If diagnosed in advanced stages, it often cannot be cured.
There is a critical need for easily accessed, accurate, and economical Point-of-Care diagnostics.
Improved Diagnostics
LiverScope® provides instant accurate results, without the need for image interpretation or histological examination – overcoming critical deficiencies of standard diagnostic modalities.
Livivos’s technology transforms liver disease diagnostics, responding to a fast-growing demand for effective and broadly available testing. LiverScope® will significantly advance liver testing on a larger scale and will support accurate evaluation of the response to treatments.
Other liver disease diagnostic modalities are invasive, expensive or inaccurate:
Liver Disease Prevalence
There are 64 million individuals with NAFLD in the United States and 52 million total in Germany, France, Italy, and the UK. The global prevalence of NAFLD is estimated to be 24%. 1.75 million individuals die of liver disease each year. In addition, a high prevalence of obesity has been reported in South America, Asia, and the Middle East. The number of affected people and the economic burden are expected to increase.
Clinical markets benefiting from effective liver disease diagnostics
Point-of-Care Diagnosis.BROAD AND PERIODIC TESTING
Preventive medicine, clinical triage for the millions of patients with suspected NAFLD, and accurate over-time treatment monitoring.
Evaluating Drug Efficacy.MORE EFFECTIVE AND FASTER EVALUATION
Supporting regulatory clinical trials. There is a rapid increase in the number of liver disease drugs undergoing FDA evaluation. Livivos’s technology provides biomarkers to quantify the evolution of steatosis.
Long Term Evaluation.POST-MARKET EFFICACY MONITORING
Monitoring of drug effectiveness after drug approval – especially for NASH drugs with anti-steatotic mechanisms of action – as they enter the clinical market.
